PE20191486A1 - COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER - Google Patents

COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER

Info

Publication number
PE20191486A1
PE20191486A1 PE2019001872A PE2019001872A PE20191486A1 PE 20191486 A1 PE20191486 A1 PE 20191486A1 PE 2019001872 A PE2019001872 A PE 2019001872A PE 2019001872 A PE2019001872 A PE 2019001872A PE 20191486 A1 PE20191486 A1 PE 20191486A1
Authority
PE
Peru
Prior art keywords
quinolin
imidazo
cancer
treatment
ona
Prior art date
Application number
PE2019001872A
Other languages
English (en)
Inventor
Kurt Gordon Pike
Bernard Christophe Barlaam
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20191486A1 publication Critical patent/PE20191486A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

La presente invencion se refiere a un compuesto de formula I y sales aceptables del mismo, donde: R1 es H o D (Deuterio). Son compuestos preferidos: 4,6-Dideutero-7-fluoro-1-isopropil-3-metil-8-[6-[3-(1-piperidil)propoxi]-3-piridil]imidazo[4,5-c]quinolin-2-ona y 4-Deutero-7-fluoro-1-isopropil-3-metil-8-[6-[3-(1-piperidil)propoxi]-3-piridil]imidazo[4,5-c] quinolin-2-ona. Dichos compuestos son derivados de imidazo [4,5-c] quinolin-2-ona deuterados, los cuales son moduladores selectivos de la quinasa de la ataxia telangiectasia mutada ("ATM"), siendo utiles en el tratamiento o prevencion del cancer. Tambien se refiere a una composicion farmaceutica.
PE2019001872A 2017-03-16 2018-03-15 COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER PE20191486A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472080P 2017-03-16 2017-03-16
PCT/EP2018/056516 WO2018167203A1 (en) 2017-03-16 2018-03-15 Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
PE20191486A1 true PE20191486A1 (es) 2019-10-18

Family

ID=61801891

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001872A PE20191486A1 (es) 2017-03-16 2018-03-15 COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER

Country Status (25)

Country Link
US (2) US20200087300A1 (es)
EP (1) EP3596076A1 (es)
JP (1) JP2020514344A (es)
KR (1) KR20190129923A (es)
CN (1) CN110431139B (es)
AU (1) AU2018234985B2 (es)
BR (1) BR112019018723A2 (es)
CA (1) CA3055258A1 (es)
CL (1) CL2019002527A1 (es)
CO (1) CO2019010029A2 (es)
CR (1) CR20190429A (es)
DO (1) DOP2019000228A (es)
EA (1) EA038233B1 (es)
EC (1) ECSP19066134A (es)
IL (1) IL269272A (es)
JO (1) JOP20190209A1 (es)
MA (1) MA49884A (es)
MX (1) MX2019010898A (es)
NI (1) NI201900094A (es)
PE (1) PE20191486A1 (es)
PH (1) PH12019502086A1 (es)
SG (1) SG11201908065YA (es)
TW (1) TW201843151A (es)
UA (1) UA124554C2 (es)
WO (1) WO2018167203A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV15575A (lv) * 2019-12-20 2021-06-20 Latvijas Organiskās Sintēzes Institūts Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
TW202216209A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atm抑制劑之組合
US11919899B2 (en) * 2020-09-21 2024-03-05 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
UA106074C2 (uk) * 2009-06-04 2014-07-25 Новартіс Аг ПОХІДНІ 1H-ІМІДАЗО[4,5-c]ХІНОЛІНОНУ
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (es) * 2014-05-08 2018-04-21
JP6791873B2 (ja) * 2015-04-02 2020-11-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ イミダゾロニルキノリンおよびａｔｍキナーゼ阻害剤としてのその使用
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer

Also Published As

Publication number Publication date
KR20190129923A (ko) 2019-11-20
TW201843151A (zh) 2018-12-16
JOP20190209A1 (ar) 2019-09-12
IL269272A (en) 2019-11-28
AU2018234985A1 (en) 2019-10-24
WO2018167203A1 (en) 2018-09-20
CN110431139B (zh) 2022-07-05
JP2020514344A (ja) 2020-05-21
US20210347775A1 (en) 2021-11-11
CA3055258A1 (en) 2018-09-20
MX2019010898A (es) 2019-11-07
CR20190429A (es) 2019-11-12
US20200087300A1 (en) 2020-03-19
PH12019502086A1 (en) 2020-03-09
CN110431139A (zh) 2019-11-08
ECSP19066134A (es) 2019-09-30
UA124554C2 (uk) 2021-10-05
DOP2019000228A (es) 2019-09-30
BR112019018723A2 (pt) 2020-04-07
CL2019002527A1 (es) 2019-11-22
MA49884A (fr) 2020-06-24
EP3596076A1 (en) 2020-01-22
NI201900094A (es) 2020-03-18
EA201992090A1 (ru) 2020-03-06
CO2019010029A2 (es) 2019-09-30
AU2018234985B2 (en) 2020-04-02
EA038233B1 (ru) 2021-07-28
SG11201908065YA (en) 2019-09-27

Similar Documents

Publication Publication Date Title
PE20191486A1 (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER
NI201800033A (es) Derivados de 8-[6-[3-(amino)propoxi]-3piridil]-1-isopropil-imidazo[4, 5-c]quinolin -2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer.
CL2018001146A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CY1121195T1 (el) Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
CO2018002060A2 (es) Compuestos farmacéuticos
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CY1117638T1 (el) Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης
AR100431A1 (es) Compuestos de pladienolida piridina y métodos de uso
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
MX2018004664A (es) Antagonistas de ep4.
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
TR201900680T4 (tr) CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri.
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
CL2019001023A1 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
PE20181895A1 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer
CY1123185T1 (el) Παραγωγα ινδολιου
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer